Supplemental Figure 1: FOXM1 mRNA level analysis in 48 ovarian tissues   FOXM1 p value parameter N=48 <10 >10, <50 >50, <100 >100, <200 >200 tissue normal 8 8 (100%) p=0.0003 cancer 40 5 (12.5%) 10 (25%) 12 (30%) 13 (32.5%) Stage 1 and 2 17 2 (11.8%) 5 (29.4%) 8 (47.1%) NS 3 and 4 23 3 (13.0%) 8 (34.8%) 7 (30.4%) 5 (21.7%) Differentiation 36 well 1 1 (100%) moderate 13 1 (7.7%) 4 (30.8%) 5 (38.5%) 3 (23.1%) poor 22 3 (13.6% 5 (22.7%) 4 (18.2%) 10 (45.5%) Histology serous 30 3 (10%) 9 (30%) 8 (26.7%) 10 (33.3%) endometrioid 5 1 (20%) 3 (60%) Serous-Endometriod 3 1 (33.3%) 2 (66.7%) Mucinous Clear cell

Supplemental Figure 2: Five HGS-OVCA patients clinical features Age Stage Histology Initial treatment Platinum status Comments #1 74 IV-eff. Primary peritoneal serous Initial cytoreduction surgery IV carbo/tax x 6 cycles Platinum resistant -Multidrug resistant sample obtained at progression after 4 lines of chemotherapy #2 66 Platinum refractory -Sample taken at progression after 5th cycle of initial chemotherapy -Died 4 months after initial diagnosis #3 64 IV-liver Ovarian serous Neoadjuvant carbo/tax x 3 Interval cytoreduction surgery Adjuvant carbo/tax x2 -Sample taken at time of interval debulking with partial response. --After surgery liver mets grew and pt died 10 months after dx. #4 65 IIIC Debulking surgery IVcarbo/tax/bev x6, maintenance -Sample taken at initial surgery -Progressed at 6 months after completion of chemotherapy #5 80 IV carbo/tax x 3 cycles Unknown -Sample from initial surgery prior to chemo -Transfer of care to outside facility after 3rd cycle of chemo and no further clinical data available